| Title: | Impact of metformin on intervertebral disc degeneration in patients with diabetes: a prospective cohort study from the UK biobank |
| Journal: | Diabetology & Metabolic Syndrome |
| Published: | 11 Dec 2025 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/41382209/ |
| DOI: | https://doi.org/10.1186/s13098-025-02050-7 |
Publication 17238
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
ObjectiveIntervertebral disc degeneration (IDD) is a major contributor to low back pain and disability. Emerging evidence suggests that type 2 diabetes mellitus (T2DM) accelerates IDD progression, while metformin, a first-line treatment for T2DM, may offer protective effects. This study aimed to evaluate the association between metformin use and long-term IDD risk in T2DM patients using data from the UK Biobank.MethodsA prospective cohort of 20,350 individuals with T2DM was analyzed, including 11,158 metformin users and 9192 non-users. The primary outcome was incident IDD, identified via ICD-10 codes. Cox proportional hazards models estimated hazard ratios (HRs) for IDD, adjusting for demographic, behavioral, and clinical factors. A sensitivity analysis was performed by excluding patients with a follow-up period of less than 2 years to assess the stability of the results. Subgroup and interaction analyses explored effect modifiers. Predictive models using Cox regression were developed to estimate 5- and 13-year IDD risk, with model performance evaluated by area under the ROC curve (AUC).ResultsOver a median follow-up of 13 years, metformin use was significantly associated with a reduced risk of IDD [HR (95% CI): 0.863 (0.753-0.989), p = 0.034]. The results were robust in the sensitivity analysis[HR (95% CI): 0.862 (0.749-0.992), p = 0.039]. A significant interaction with sleep time and hypertension status were observed (P for interaction < 0.05). Predictive model AUCs for 5- and 13-year IDD risk were 0.64 (95% CI: 0.57-0.70) and 0.69 (95% CI: 0.66-0.73), respectively.ConclusionsThese findings suggest that metformin may lower long-term IDD risk in T2DM patients, particularly those with hypertension, highlighting its potential role in IDD prevention and the need for further interventional studies.</p>
15 Authors
- Jianan Chen
- Nianchun Liao
- Bo Gao
- Tongzhou Liang
- Wenjun Hu
- Zaoqiang Zhang
- Wangim Choi
- Huihong Shi
- Song Liu
- Yanbo Chen
- Youxi Lin
- Zhihuai Deng
- Xianjian Qiu
- Dongsheng Huang
- Wenjie Gao
1 Application
| Application ID | Title |
|---|---|
| 117320 | Identifying potential interactions and crosstalk between brain and bone during in degenerative or rheumatic bone disease using UK Biobank |
Enabling scientific discoveries that improve human health